gabaa receptor

GABAA receptor agent 1 has strong anticonvulsant activity and is a high affinity ligand of GABAA receptor.

Compound S28, also known as GABAA receptor modulator-3, regulates the (γ-aminobutyric acid)A receptor (GABAA receptor), exhibiting EC50 values of 56 nM for the α1β2γ2 subtype and 10 nM for the α4β3δ subtype. In rats, it demonstrates favorable pharmacokinetic properties and slight toxicity. The threshold dose for loss of righting reflex (LORR) in rats is 23.3 μmol kg. Furthermore, Compound S28 shows potential to alleviate postpartum depression.

GABAA receptor agent 6 (compound 2027) is a potent γ-GABAAR antagonist with low cellular membrane permeability (Ki = 0.56 μM) [1].

GABAA Receptor Agent 5 (compound 018) serves as a potent γ-GABAAR antagonist, possessing a Ki of 0.020 μM. This compound exhibits γ-GABAAR antagonist properties, yet it demonstrates low cellular membrane permeability [1].

GABAA receptor modulator-3 (compound 3b) is a positive allosteric modulator (PAM). It inhibits the peak current and steady-state current of α1β3γ2 GABAAR with IC50 values of 671 μM and 64 μM, respectively.

GABAA receptor agent 7 (compound 5c) is a potent positive modulator of the GABAA receptor with anticonvulsant activity in vitro and in vivo, and low neurotoxicity, making it suitable for epilepsy research [1].

GABAA receptor agent 4 (compound 1e) is a potent antagonist of γ-GABAAR, exhibiting a Ki of 0.18 µM, and demonstrates immunomodulatory potential by effectively rescuing the inhibition of T cell proliferation [1].

GABAA receptor modulator-4 (Compound 4) acts as a negative allosteric modulator of the GABAA receptor. It inhibits the peak and steady-state currents mediated by the α1β3γ2 GABAA receptors, with an IC50 of 10 μM for both.

GABAA receptor agent 2 TFA is a potent, high-affinity GABAA receptor antagonist with an IC50 of 24 nM [human α1β2γ2GABAA-expressing tsA201 cells] and a Ki of 28 nM [rat GABAA receptor]. GABAA receptor agent 2 TFA has no effect on four human GABA transport proteins [hGAT-1, hBGT-1, hGAT-2, and hGAT-3].

GABAA receptor agent 8 (compound 5e) is a potent positive modulator of the GABAA receptor, exhibiting anticonvulsant activity in both in vitro and in vivo studies, with low neurotoxicity, indicating its potential in epilepsy research [1].

GABAA receptor agonist 2 (compound 4c) is a highly potent compound that exhibits anti-depressive properties in classical mouse models of depression, such as the FST and TST. By binding to the GABA binding site on the GABAA receptor, it produces GABAergic effects. Notably, compound 4c holds promise for depression research [1].

GABAA receptor agonist 1 (compound 3e) is a potent agonist that binds to the GABA binding site of the GABAA receptor, producing GABAergic effects and exhibiting anti-depression activities in classical mouse models of FST and TST, indicating its potential in depression research [1].

GABAA receptor modulator-2 (Compound 20) is a selective, orally active α5-GABAAR negative conformation modulator (Ki: 4.1 nM) that exhibits high metabolic stability and a good central nervous system safety profile.

α5-GABAA receptor modulator 1 (Compound A-4) is a selective silent allosteric modulator (SAM) targeting the α5 subunit of GABAA receptors, useful for research into central nervous system (CNS) disorders.

DMCM hydrochloride is a non-selective fully inverse agonist of benzodiazepine. DMCM showed significant differences in human recombinant GABAA αxβ3γ2 receptor subtypes. For α1, α2, α3, and α5 receptors, their Kis were 10 nM, 13 nM, 7.5 nM, 2.2 nM, respectively.

ELB-139 is a GABAA receptor agonist that can be used to study depression and epilepsy.

BL-1020 Mesylate (CYP-1020 Mesylate) is an orally available GABA A receptor agonist and D2 antagonist that decreases dopamine activity and enhances GABAA activity.BL-1020 Mesylate has been used in the study of schizophrenia, Alzheimer's disease, and bi-directional cognitive impairment.

NS-2710 is a non-selective GABA(A) receptor partial agonist for the study of anxiety disorders.

Pazinaclone is a non-benzodiazepine (GABAA) partial agonist with sedative and anxiolytic activity.

Golexanolone (Golexanolona) is a novel GABA-A receptor-modulating steroid antagonist that reduces peripheral inflammation and neuroinflammation and improves cognitive and motor function in rats with chronic hyperammonemia, and may be used to study hepatic encephalopathy.

Suriclone (RP 31264) is a selective cyclic pyrrolidone analog with sedative and anxiolytic activity, but not significant sedative effects.Suriclone shows its effects by modulating GABA-A receptors.

Darigabat (PF-06372865) is an orally active and selective GABAA receptor modulator that crosses the blood-brain barrier and exhibits anxiolytic activity, with Ki values of 2.9 nM, 21 nM, and 134 nM for α2, α1 PAM, and α2 PAM, respectively.Darigabat is used in the study of anxiety disorders and epilepsy.

Lirequinil (Ro 41-3696) is a small molecule GABAA receptor agonist utilized in the study of neurological disorders.

Broflanilide is metabolized to desmethyl-broflanilide, which is a potent antagonist at the insect resistant-to-dieldrin GABA receptor and inhibits S. litura RDL GABAR (IC50: 1.3 nM).